Abstract
Rationale
Buprenorphine is widely used as an analgesic drug and it is also increasingly considered for maintenance and detoxification of heroin addicts. It is a potent µ-receptor partial agonist with a long duration of action. An inverted U-shaped dose-effect curve for buprenorphine conditioned place preference (CPP) has been shown previously.
Objectives
We re-evaluated the CPP effects of buprenorphine by taking into account the particular kinetic properties of the drug in the design of the experiments.
Methods
An unbiased CPP procedure with different wash-out periods was used to investigate a possible influence of the long duration of action of buprenorphine on the outcome of the experiment.
Results
Following a standard procedure (drug and vehicle conditioning on alternating days), the inverted U-shaped dose-effect curve was reproduced (no CPP at 0.01 mg/kg, significant CPP at 0.1 and 1.0 mg/kg, and no CPP at 3.16 and 10 mg/kg, IP). However, when there was a 48 h interval between drug and vehicle conditioning, there was a clear tendency towards CPP for the two highest doses, and when there was a 72-h interval between drug and vehicle conditioning, significant CPP was seen. Naloxone (0.215 mg/kg SC), haloperidol (0.215 mg/kg IP) and U-50488 (1.0 mg/kg SC) blocked buprenorphine (1.0 mg/kg) CPP. Buprenorphine CPP was also blocked by coadministration of naltrindole (3.16 mg/kg IP), nor-binaltorphimine (4.64 mg/kg SC), and naloxonebenzoylhydrazone (0.464 mg/kg SC). However, the data suggest that blockade by the three latter drugs was due to state-dependency effects. Buprenorphine at doses of 1.0 mg/kg and higher also produced locomotor sensitization across the 3 drug conditioning days. The sensitization produced by 1.0 mg/kg buprenorphine was blocked by haloperidol and U-50488, but not by naloxone, naltrindole, nor-binaltorphimine, and naloxonebenzoylhydrazone.
Conclusions
The present results suggest that the reported lack of CPP effects at high doses of buprenorphine may be due to factors in the experimental design, resulting in a carry-over effect from drug- to vehicle conditioning. They also suggest that buprenorphine, like other opiates, produces its CPP effects via µ-receptors, although κ-antagonistic mechanisms also appear to be involved. The implications of these findings for the safety of buprenorphine for human use are discussed.
Similar content being viewed by others
References
Ableitner A, Herz A (1989) Limbic brain structures are important sites of kappa-opioid receptor-mediated actions in the rat: a [14C]-2-deoxyglucose study. Brain Res. 478:326–336
Amass L, Kamien JB, Mikulich SK (2001) Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 61:173–181
Anon (2001) Editorial. Drugs Future 26:896–897
Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3:477–489
Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141–1146
Boas R, Villiger J (1985) Clinical actions of fentanyl and buprenorphine. Br J Anaesth 57:192–196
Brookoff D (1993) Abuse potential of various opioid medications. J Gen Int Med 8:688–690
Brown EE, Finlay JM, Wong JTF, Damsma G, Fibiger HC (1991) Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 256:119–126
Cone EJ, Gorodetzky CW, Yousefnejad D, Darwin WD (1985) 63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces. J Chromatogr 337:291–300
Cowan A, Lewis JW (eds) (1995) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss, New York
Cowan A, Lewis JW, MacFarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537–545
Dum JE, Herz A (1981) In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 74:627–633
Dykstra LA (1983) Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 226:317–323
Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30–42
Foltin RW, Fischman MW (1994) Effects of buprenorphine on the self-administration of cocaine by humans. Behav Pharmacol 5:79–89
France CP, Jacobson AE, Woods JH (1984) Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J Pharmacol Exp Ther 230:652–657
Fudala PJ, Iwamoto ET (1990) Conditioned aversion after delay conditioning with amphetamine. Pharmacol Biochem Behav 35:89–92
Gaiardi M, Bartoletti M, Bacchi A, Gubellini C, Babbini M (1997) Motivational properties of buprenorphine as assessed by place and taste conditioning in rats. Psychopharmacology 130:104–108
Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD (1984) Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology 84:147–154
Gysling K, Wang RY (1983) Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res 277:119–127
Hambrook JM, Rance MJ (1976) The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW (ed) Opiates and endogenous opioid peptides. Elsevier, Amsterdam, pp 295–301
Hand TH, Stinus L, Le Moal M (1989) Differential mechanisms in the acquisition and expression of heroin-induced place preference. Psychopharmacology 98:61–67
Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688–695
Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501–516
Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483–488
Kalivas PW, Duffy P (1987) Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J Pharmacol Exp Ther 241:204–212
Lattanzi R, Negri L, Giannini E, Schmidhammer H, Schutz J, Improta G (2001). HS-599: a novel long acting opioid analgesic does not induce place-preference in rats. Br J Pharmacol 134:441–447
Leander DJ (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445–1447
Leone P, Di Chiara G (1987) Blockade of D-1 receptors by SCH23390 antagonizes morphine- and amphetamine-induced place preference conditioning. Eur J Pharmacol 135:251–254
Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363–372
Liguori A, Morse WH, Bergman J (1996) Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277:462–472
Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Hoog C (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299:1056–1065
Mucha RF, Herz A (1985) Motivational properties of kappa nd mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274–280
Ohtani M, Shibuya F, Kotaki H, Uchino K, Saitoh Y, Nakagawa F (1989) Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography-chemical ionization mass sprectrometry. J Chromatogr 487:469–475
Ohtani M, Kotaki H, Sawada Y, Iga T (1995) Comparative analysis of buprenorphine- and norbuprenorphine-induced anagesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505–510
Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T (1997) Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428–433
Pchlintsev MV, Gorbacheva EN, Zvartau EE (1991) Simple methodology of assessment of analgesics’ addictive potential in mice. Pharmacol Biochem Behav 39:873–876
Pontani RB, Vadlamani NL, Misra AL (1985) Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15:287–297
Preston KL, Jasinski DR (1991) Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28:49–82
Rance MJ, Dickens JM (1978) The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree J, Terenius L (eds) Characteristics and functions of opioids. Elsevier/North Holland Biomedical Press, Amsterdam, pp 65–66
Rance MJ, Lord JAH, Robinson T (1980) Biphasic dose-response to buprenorphine in the rat tail-flick assay: effect of naloxone pretreatment. In: Way EL (Ed) Endogenous and exogenous opiate agonists and antagonists. Pergamon Press, New York, pp 387–390
Richards ML, Sadee W (1985) Buprenorphine is an antagonist at the kappa opioid receptor. Pharmacol Res 2:178–181
Rosenbaum JS, Holford NHG (1985) In vivo receptor binding of opioid drugs at the mu site. J Pharmacol Exp Ther 233:735–740
Rowlett JK, Gibson TR, Bardo MT (1994) Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats. Pharmacol Biochem Behav 49:241–245
Schulz R, Herz A (1976) The guinea-pig ileum as an in vitro model to analyze dependence liability of narcotic drugs. In: Kosterlitz HW (ed) Opiates and endogenous opioid peptides. Elsevier, Amsterdam, pp 319–326
Shippenberg TS, Herz A (1986) Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75:563–566
Shuster L, Webster GW, Yu G (1975) Increased running response to morphine in morphine-pretreated mice. J Pharmacol Exp Ther 192:64–67
Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154:230–242
Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025–1030
Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613–672
Tzschentke TM (2001) Buprenorphine in conditioned place preference studies in the rat. Soc Neurosci Abstr 27:647.18
Tzschentke TM (2002) Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 161:1–16
Tzschentke TM, Bruckmann W (2002) Temporal and pharmacological determinants of buprenorphine conditioned place preference. Behav Pharmacol 13:507
Villiger J, Taylor K (1981) Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 29:2699–2708
Wall A, Hinson RE, Schmidt E, Johnston C, Streather A (1990) Place conditioning with d-amphetamine: the effect of the CS-UCS interval and evidence of a place avoidance. Anim Learn Behav 18:393–400
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569–580
Walter DS, Inturrisi CE (1995) Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW (eds) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss, New York, pp 113–135
Wilding IR, Davis SS, Rimoy GH, Rubin P, Kurihara-Bergstrom T, Tipnis V, Berner B, Nightingale J (1996) Pharmacokinetic evaluation of transdermal buprenorphine in man. Int J Pharm 132:81–87
Zaveri N, Polgar WE, Olsen CM, Kelson AB, Grundt P, Lewis JW, Toll L (2001) Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 428:29–36
Acknowledgements
The excellent technical assistance of Mr. W. Bruckmann is greatly acknowledged. Thanks to Dr. Alan Cowan for helpful comments on earlier versions of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tzschentke, T.M. Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology 172, 58–67 (2004). https://doi.org/10.1007/s00213-003-1626-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1626-4